Revenue Update on Eiger BioPharmaceuticals, Inc. – Common Stock(NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc. – Common Stock(NASDAQ:EIGR) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-1.53.

Eiger BioPharmaceuticals, Inc. – Common Stock (EIGR) remained unchanged at the close of Friday session. Even as the volume increased to 13,553 ,the shares failed to make any impression and ended at 0 points or 0.00% at $10.4. The trading session commenced at $10.35 and the stock hit a high of $10.55 and touched $10.15 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $23.1 and the 52-week low is $10.15. The company has a market cap of $87 M and has approximately 83,61,196 outstanding shares.

Several Insider Transactions has been reported to the SEC. On Nov 21, 2016, Jeffrey S Glenn (director) purchased 15,460 shares at $12.81 per share price.Also, On Aug 19, 2016, David A Cory (CEO) purchased 1,562 shares at $15.70 per share price.On Aug 19, 2016, James P Shaffer (Chief Business Officer) purchased 3,125 shares at $15.70 per share price, according to the Form-4 filing with the securities and exchange commission.

Add Comment